Why Is KRYSTAL BIOTECH INC (KRYS) Stock Moving Today?

KRYS stock fell 8.37% to $312.57 in the session, driven by mixed second-quarter results and investor reaction to guidance. While Krystal Biotech reported GAAP earnings per share of $1.79, which beat estimates by $0.16, revenue of $119.22 million came in $1.82 million below forecasts. The company also outlined a 2026 non-GAAP operating expense range of $175 million to $195 million, and investors appeared to weigh the revenue shortfall and evolving financial commitments.

What Happened

Krystal Biotech reported second-quarter 2026 results on August 3, 2026, with GAAP EPS of $1.79, exceeding the expected $1.63. However, revenue of $119.22 million, while up 24% year over year, fell short of the $121.06 million forecast. The company attributed the revenue miss to timing of VYJUVEK sales and the impact of Germany pricing accruals. Despite robust global VYJUVEK revenue of $119.2 million for the quarter and $965.9 million since launch, the stock declined on concerns over near-term revenue visibility and the outlined expense guidance. The firm also announced it is advancing KB801 into a pivotal trial after discontinuing a clinical study with no safety concerns observed.

What The Data Shows

Krystal Biotech ended the quarter with $1.1 billion in cash and a net margin of 53.9%. The stock has traded between $130.50 and $382.54 over the past 52 weeks. Recent insider transactions include four sales totaling $15.9 million in the last 90 days, with the most recent filing on June 26. Additionally, Donald J. Trump sold between $15,001 and $50,000 in the stock on May 15. The stock’s beta of 0.50 suggests it is less volatile than the broader market, but the sharp intraday move reflects immediate investor reaction to the earnings report and guidance.

What To Watch

The company has no upcoming earnings reports in the near term. Investors should monitor coverage breadth and analyst commentary, particularly as B of A Securities and TD Cowen have both raised price targets to $396 and $403 respectively, maintaining Buy ratings.